Mediq Eesti OÜ
Väljaotsa 2, Saue
Mediq expands in Nordics with UpViser Oy acquisition
Mediq has acquired UpViser Oy, a Finnish leading provider of surgical and endotherapy products that focuses on gastroenterology, gynecology, plastic surgery and urology. Its customers include the largest hospitals in the Nordic countries. The acquisition of UpViser and its subsidiaries in Sweden, Denmark, Norway and Estonia is an important step in Mediq’s strategy to be the leading European player in device-led hospital solutions. ‘UpViser is an innovative company that strengthens our ability to provide solutions and services to hospitals and enables us to accelerate our growth in the Nordics. We gladly welcome their team of highly skilled professionals to our group’, says Mediq CEO Christian Wojczewski.
The acquisition complements Mediq’s Nordic Hospital Solutions portfolio aimed to support healthcare institutions and professionals in providing best possible care. It also provides access to new product segments such as endotherapy. ‘Over the years, UpViser has built partnerships with leading suppliers. We are impressed with their track record and believe that our complementary strengths and culture make UpViser and Mediq an excellent combination’, Wojczewski states.
Vice President, Nordic Hospital Solutions
+358 50 429 2510
UpViser Oy was founded in 2008 in Vantaa and is active throughout Finland, Sweden, Norway and Denmark. The main customers are surgical departments with focus on four key areas: plastic surgery, urology, gynecology and gastroenterology.
Every day, millions of patients and the dedicated professionals who care for them rely on the supply of medical devices and care solutions from Mediq. As a reliable partner for patients, healthcare professionals and healthcare insurers, Mediq continuously focuses on improving healthcare outcomes and the affordability of healthcare. Mediq was founded in 1899 and has leading market positions in 13 European countries. The head office is located in Utrecht.
We have the joy to announce that Dr. Jussi Kosola has started the SVF knee ...
The newly Calistar S study published in the International Urogynecology Jou...
Simunec 2020 - Treatment of Grade 3 and 4 Osteoarthritis...
Cellular Optimization of Nanofat: Comparison
of Two Nanofat Processing Dev...